Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | FPR2 | P25090 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17144996 | 0.91 | KDM4E (0.65) | KDM4EALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL17144809 | 0.86 | CYP1A1 (0.54) | KDM4EALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL3628069 | 0.86 | NPC1 (0.61) | KDM4EALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL17144923 | 0.85 | PDGFRB (0.59) | KDM4EALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL17145111 | 0.85 | ALDH1A1 (0.61) | KDM4EALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL5950603 | 0.84 | NPC1 (0.59) | KDM4EALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL18492964 | 0.83 | HDAC8 (0.58) | KDM4EALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL13680448 | 0.81 | KDM4E (0.58) | KDM4EALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL17144798 | 0.81 | CYP1A1 (0.61) | KDM4EALDH1A1NPC1RAB9AMEN1 | |
| SCHEMBL29992900 | 0.80 | RAB9A (0.64) | KDM4EALDH1A1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017475-B2 | Anti-vasculature and anti-tubulin combretastatin analogs for treatment of cancer | XAVIER UNIVERSITY OF LOUSIANA (US) | 2018-07-10 | — | — | US | claimed |
| US-20170044103-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | XAVIER UNIVERSITY OF LOUISIANA | 2017-02-16 | — | — | US | claimed |
| WO-2015153252-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | XAVIER UNIVERSITY OF LOUISIANA (US) | 2015-10-08 | — | — | WO | claimed |
| US-10017475-B2 | Anti-vasculature and anti-tubulin combretastatin analogs for treatment of cancer | XAVIER UNIVERSITY OF LOUSIANA (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170044103-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | XAVIER UNIVERSITY OF LOUISIANA | 2017-02-16 | — | — | US | disclosed |
| US-20170044103-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | XAVIER UNIVERSITY OF LOUISIANA | 2017-02-16 | — | — | US | disclosed |
| WO-2015153252-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | XAVIER UNIVERSITY OF LOUISIANA (US) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044103-A1 | ANTI-VASCULATURE AND ANTI-TUBULIN COMBRETASTATIN ANALOGS FOR TREATMENT OF CANCER | FLT4, TUBB3, TUBA4A | KDM4E 3658/4885ALDH1A1 3306/4885NPC1 2308/4885 |
| US-10017475-B2 | Anti-vasculature and anti-tubulin combretastatin analogs for treatment of cancer | FLT4, TUBB3, TUBA4A | KDM4E 3658/4885ALDH1A1 3306/4885NPC1 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.